368 related articles for article (PubMed ID: 27418821)
1. Potential treatment benefits and safety of roflumilast in COPD: a systematic review and meta-analysis.
Yuan L; Dai X; Yang M; Cai Q; Shao N
Int J Chron Obstruct Pulmon Dis; 2016; 11():1477-83. PubMed ID: 27418821
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis.
Yan JH; Gu WJ; Pan L
Pulm Pharmacol Ther; 2014 Feb; 27(1):83-9. PubMed ID: 23624309
[TBL] [Abstract][Full Text] [Related]
3. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.
Pinner NA; Hamilton LA; Hughes A
Clin Ther; 2012 Jan; 34(1):56-66. PubMed ID: 22284994
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.
Oba Y; Lone NA
Ther Adv Respir Dis; 2013 Feb; 7(1):13-24. PubMed ID: 23197074
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease.
Janjua S; Fortescue R; Poole P
Cochrane Database Syst Rev; 2020 May; 5(5):CD002309. PubMed ID: 32356609
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
Chong J; Leung B; Poole P
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD002309. PubMed ID: 28922692
[TBL] [Abstract][Full Text] [Related]
7. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
Chong J; Leung B; Poole P
Cochrane Database Syst Rev; 2013 Nov; (11):CD002309. PubMed ID: 24190161
[TBL] [Abstract][Full Text] [Related]
9. Roflumilast: a novel treatment for chronic obstructive pulmonary disease.
Reid DJ; Pham NT
Ann Pharmacother; 2012 Apr; 46(4):521-9. PubMed ID: 22433610
[TBL] [Abstract][Full Text] [Related]
10. Roflumilast in the management of chronic obstructive pulmonary disease.
Lipari M; Benipal H; Kale-Pradhan P
Am J Health Syst Pharm; 2013 Dec; 70(23):2087-95. PubMed ID: 24249758
[TBL] [Abstract][Full Text] [Related]
11. Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials.
Rennard SI; Sun SX; Tourkodimitris S; Rowe P; Goehring UM; Bredenbröker D; Calverley PM
Int J Chron Obstruct Pulmon Dis; 2014; 9():657-73. PubMed ID: 25018629
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for the discontinuation of roflumilast in patients with chronic obstructive pulmonary disease.
Kim KH; Kang HS; Kim JS; Yoon HK; Kim SK; Rhee CK
Int J Chron Obstruct Pulmon Dis; 2017; 12():3449-3456. PubMed ID: 29270006
[TBL] [Abstract][Full Text] [Related]
13. Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.
Rennard SI; Calverley PM; Goehring UM; Bredenbröker D; Martinez FJ
Respir Res; 2011 Jan; 12(1):18. PubMed ID: 21272339
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
Chong J; Poole P; Leung B; Black PN
Cochrane Database Syst Rev; 2011 May; (5):CD002309. PubMed ID: 21563134
[TBL] [Abstract][Full Text] [Related]
15. Health status in patients with COPD treated with roflumilast: two large noninterventional real-life studies: DINO and DACOTA.
Kardos P; Mokros I; Sauer R; Vogelmeier CF
Int J Chron Obstruct Pulmon Dis; 2018; 13():1455-1468. PubMed ID: 29765213
[TBL] [Abstract][Full Text] [Related]
16. Clinical Considerations for Roflumilast: A New Treatment for COPD.
Kelly Freeman ML
Consult Pharm; 2012 Mar; 27(3):189-93. PubMed ID: 22421519
[TBL] [Abstract][Full Text] [Related]
17. Roflumilast: doubtful efficacy but clear harms in COPD.
Prescrire Int; 2013 Jan; 22(134):5-9. PubMed ID: 23367674
[TBL] [Abstract][Full Text] [Related]
18. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF
Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586
[TBL] [Abstract][Full Text] [Related]
19. Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis.
Luo J; Wang K; Liu D; Liang BM; Liu CT
Respir Res; 2016 Feb; 17():18. PubMed ID: 26887407
[TBL] [Abstract][Full Text] [Related]
20. Roflumilast--a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD.
Taegtmeyer AB; Leuppi JD; Kullak-Ublick GA
Swiss Med Wkly; 2012; 142():w13628. PubMed ID: 22833385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
